First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

NCT01521715 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced and/or Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Clear-cell Metastatic Renal Cell Carcinoma

Interventions

DRUG: Pazopanib

Sponsor

iOMEDICO AG

Collaborators

[object Object]